“We plan to continue the development of AE37 for
Post# of 36537
(Total Views: 312)
Posted On: 08/13/2020 9:17:56 PM
“We plan to continue the development of AE37 for breast, prostate and other cancers including bladder cancer. Upon funding we plan to initiate a Phase II trial of AE37 in bladder cancer at a premier cancer institute. Discussions on confidential trial design and conduct are ongoing. “
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼